TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22246115

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 1272
Study: 20225994

Group type: EXPERIMENTAL
Intervention: Nebicapone 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nebicapone 200 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18404296

Group type: EXPERIMENTAL
Intervention: Preoperative decolonization protocol using mupirocin ointment (twice daily) and chlorhexidine bath (once daily) for 5 days before surgery.
Number of subjects: 636

Group type: COMPARATOR
Intervention: Concurrent control group (patients of surgeons who did not participate in the intervention study).
Number of subjects: 636

Group type: COMPARATOR
Intervention: Preintervention control group (patients of participating surgeons who had undergone elective TJA during the year before the study).
Number of subjects: 636
Study: 15811057

Group type: EXPERIMENTAL
Intervention: CHX 0.2%+alcohol (Corsodyl)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CHX 0.05%+CPC 0.05% (Perio‐Aid Maintenance)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11922549

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg)
Number of subjects: 5241

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg)
Number of subjects: 5241
Study: 10755770

Group type: EXPERIMENTAL
Intervention: Intensive dietary advice
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine dietary advice (Control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 7857114

Group type: EXPERIMENTAL
Intervention: Jessner's solution and 35% trichloroacetic acid (single application)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5% fluorouracil cream (twice daily applications for 3 weeks)
Number of subjects: 15
Study: 2023750

Group type: EXPERIMENTAL
Intervention: MK-507 given every 8 or 12 hours for 4 days
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: sezolamide given every 8 hours for 4 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo given every 8 or 12 hours for 4 days
Number of subjects: 82
Study: 7112797

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals 200 mg daily
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 31270902

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 42
Study: 30066248

Group type: EXPERIMENTAL
Intervention: Lung-RADS categorization by seven observers
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: Lung-RADS categorization
Number of subjects: 3360
Study: 27859478

Group type: EXPERIMENTAL
Intervention: Functional Chewing Training (FuCT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional oral motor exercises (Control)
Number of subjects: 80
Study: 26255012

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin sodium (LMWHS) 2,500 U subcutaneously, twice a day for 5 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Heparin sodium 12,500 U intravenously for 24 hours for 5 days
Number of subjects: 36
Study: 23140479

Group type: EXPERIMENTAL
Intervention: Masked Gabor patches presented in the fovea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked Gabor patches presented in near periphery (6°)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked and randomized procedures
Number of subjects: 0
Study: 21779669

Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive (Quixil™)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Mononylon 10‐0 suture (Ethicon(®))
Number of subjects: 47
Study: 19375808

Group type: EXPERIMENTAL
Intervention: Forward-planned IMRT
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 1145
Study: 16489947

Group type: EXPERIMENTAL
Intervention: Full-mouth root planing (FMRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Quadrant root planing (QRP)
Number of subjects: 20
Study: 15545163

Group type: EXPERIMENTAL
Intervention: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.)
Number of subjects: 125

Group type: COMPARATOR
Intervention: OP (ome 20 mg and placebo)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.) with NSAIDs
Number of subjects: 125

Group type: COMPARATOR
Intervention: OP (ome 20 mg and placebo) with NSAIDs
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OMC
Number of subjects: 125

Group type: COMPARATOR
Intervention: OP
Number of subjects: 125
Study: 12577391

Group type: EXPERIMENTAL
Intervention: Acanthopanax senticosus (AS) treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 47
Study: 9029427

Group type: EXPERIMENTAL
Intervention: Amplitude-modulated light exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (healthy volunteers)
Number of subjects: 20
Study: 8400346

Group type: EXPERIMENTAL
Intervention: octreotide 0.5 mg three times per day s.c.
Number of subjects: 40

Group type: COMPARATOR
Intervention: loperamide 4 mg three times per day p.o.
Number of subjects: 40
Study: 2439781

Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 mg bisoprolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (after discontinuation of active treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All doses of bisoprolol (5, 10, 20 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All doses of bisoprolol
Number of subjects: 45
Study: 29540325

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (SGLT-2i)
Number of subjects: 235064
Study: 27028341

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24682973

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 24
Study: 21169260

Group type: EXPERIMENTAL
Intervention: CAF (Cyclophosphamide, intravenous doxorubicin, and 5-fluorouracil)
Number of subjects: 458

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, intravenous methotrexate, and 5-fluorouracil) ± tamoxifen
Number of subjects: 458

Group type: COMPARATOR
Intervention: Untreated group (874 women with presumed favorable prognosis)
Number of subjects: 458
Study: 18164451

Group type: EXPERIMENTAL
Intervention: Back schools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear-avoidance training
Number of subjects: 0
Study: 16200760

Group type: EXPERIMENTAL
Intervention: Weighted combinations of sensorimotor rhythm amplitudes using a regression algorithm based on past performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single feature control of cursor movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression algorithm for cursor control
Number of subjects: 0
Study: 12690224

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg plus ethanol 0.2 g/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Caffeine 8 mg/kg plus ethanol 0.4 g/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Caffeinol (caffeine and ethanol)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Concomitant thrombolytic therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Caffeine and ethanol
Number of subjects: 23
Study: 10663449

Group type: EXPERIMENTAL
Intervention: 1.25 mg intravenous glibenclamide (Gb)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No glibenclamide (control)
Number of subjects: 20
Study: 8860761

Group type: EXPERIMENTAL
Intervention: Perioperative transfusion (packed red blood cells)
Number of subjects: 269

Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 269
Study: 1531219

Group type: EXPERIMENTAL
Intervention: 2g/m2 of etanidazole administered intravenously after 30 min (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2g/m2 of etanidazole administered intravenously after 60 min (group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2g/m2 of etanidazole administered intravenously after 120 min (group C)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Etanidazole associated with radiotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Etanidazole determination carried out with a polarographic method
Number of subjects: 34
Study: 6510061

Group type: EXPERIMENTAL
Intervention: Educational daycare
Number of subjects: 0

Group type: COMPARATOR
Intervention: No educational intervention
Number of subjects: 0
Study: 30500267

Group type: EXPERIMENTAL
Intervention: S‐REHAB
Number of subjects: 89

Group type: COMPARATOR
Intervention: STAND
Number of subjects: 89
Study: 27839981

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30 U/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60 U/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Taliglucerase alfa (dose as previously treated with imiglucerase)
Number of subjects: 15
Study: 26869678

Group type: COMPARATOR
Intervention: PRM‐151 (recombinant human pentraxin‐2) at doses of 1, 5, or 10 mg·kg(‐1) administered intravenously on days 1, 3, 5, 8, and 15.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24462229

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT-arm)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultra-brief pulse continuation electroconvulsive therapy (ECT-arm)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No add-on therapy (MED-arm)
Number of subjects: 90
Study: 22823477

Group type: EXPERIMENTAL
Intervention: Screening and promotion of target-driven, intensive treatment of multiple risk factors (n = 1678 patients)
Number of subjects: 3057

Group type: COMPARATOR
Intervention: Screening plus routine care (n = 1379 patients)
Number of subjects: 3057
Study: 20666799

Group type: EXPERIMENTAL
Intervention: Ribose cross‐linked (RCL) collagen membrane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde cross‐linked (GCL) collagen membrane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non‐cross‐linked (NCL) collagen membrane
Number of subjects: 20
Study: 17825197

Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with laparoscopy and digital subtraction angiography (group B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 75
Study: 15928469

Group type: EXPERIMENTAL
Intervention: Active compression-decompression device with impedance threshold device
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Auto-Pulse CPR
Number of subjects: 372
Study: 12088807

Group type: EXPERIMENTAL
Intervention: Sodium thiopental, 5 mg/kg (25 microg/kg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Generic propofol, 1.25 mg/kg (50 microg/kg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nongeneric propofol, 1.25 mg/kg (50 microg/kg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sodium thiopental or propofol (generic and nongeneric)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Generic propofol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nongeneric propofol
Number of subjects: 27
Study: 9793192

Group type: EXPERIMENTAL
Intervention: Gonadotropin stimulation in women with PCOS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Gonadotropin stimulation in normally ovulating women (control group)
Number of subjects: 22
Study: 8132701

Group type: EXPERIMENTAL
Intervention: Coumarin (50 mg daily for 2 years)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study: 2510561

Group type: EXPERIMENTAL
Intervention: 0.1 mg intravenous flumazenil repeated every minute until fully awake (mean 4.5 +/- 2.6 micrograms.kg‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Spontaneous recovery without flumazenil
Number of subjects: 24
Study: 31964419

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 1118
Study: 31424410

Group type: EXPERIMENTAL
Intervention: CT+Active tDCS (2mA for 30min and 0.016mA for 30min)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CT+Sham tDCS (0.016mA for 60min)
Number of subjects: 68
Study: 28568608

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg at bedtime (acute dose)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flibanserin 200 mg after chronic dosing (supratherapeutic dose)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg (positive control)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25689859

Group type: EXPERIMENTAL
Intervention: Essential oils
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sterile water (negative control)
Number of subjects: 15
Study: 23756546

Group type: EXPERIMENTAL
Intervention: PhysioGlove (PG)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Standard-cable electrocardiograms
Number of subjects: 428
Study: 21272154

Group type: EXPERIMENTAL
Intervention: Tolterodine treatment for 6 months
Number of subjects: 33
Study: 19151286

Group type: EXPERIMENTAL
Intervention: 3 mL of lidocaine 15 mg/mL with epinephrine 5 microg/mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3 mL of saline IV
Number of subjects: 40
Study: 16703746

Group type: EXPERIMENTAL
Intervention: 3D-CRT boost to 24 Gy (group III)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3D-CRT boost to 20 Gy (group II)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3D-CRT boost to 16 Gy (group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3D-CRT boost technique
Number of subjects: 36
Study: 15045199

Group type: EXPERIMENTAL
Intervention: Laser ablation for liver tumors
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Laser ablation for non-hepatic tumors
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Laser ablation overall
Number of subjects: 182
Study: 9832744

Group type: EXPERIMENTAL
Intervention: Roho mattresses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sofflex mattresses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Roho Quatro cushions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Roho mattresses and Sofflex mattresses
Number of subjects: 100
Study: 8080678

Group type: EXPERIMENTAL
Intervention: Tropisetron + Dexamethasone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Tropisetron + Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 160
Study: 2678804

Group type: EXPERIMENTAL
Intervention: Superficial thrombectomy and elastic compression (EC)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ca Heparin (0.5 mgs b.i.b.) + EC
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Venoruton (1 g, t.i.d.) + EC
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Venoruton (1 g, t.i.d.) after superficial thrombectomy + EC
Number of subjects: 83

Group type: COMPARATOR
Intervention: Elastic compression (EC)
Number of subjects: 83
Study: 175146

Group type: EXPERIMENTAL
Intervention: Negative (ego threat) presleep condition (n=14)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Positive presleep condition (n=17)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low neuroticism subjects in the negative condition
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low neuroticism subjects in the positive condition
Number of subjects: 31
Study: 31735039

Group type: EXPERIMENTAL
Intervention: Spirituality (measured by FACIT total scores)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: FACIT scores
Number of subjects: 210
Study: 27871220

Group type: EXPERIMENTAL
Intervention: Quiet Eye Training (QET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional Training (TT)
Number of subjects: 30
Study: 25496399

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention (pedometer, weight scale, asthma education DVD, and information about weight management services)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention
Number of subjects: 330

Group type: COMPARATOR
Intervention: usual care (pedometer, weight scale, asthma education DVD, and information about weight management services)
Number of subjects: 330

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 330
Study: 23247114

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both ET and RT
Number of subjects: 23
Study: 22024104

Group type: EXPERIMENTAL
Intervention: WATCH IT intervention for childhood obesity
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Self-referral via media promotion
Number of subjects: 70
Study: 18726153

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 241

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 241
Study: 17988379

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 2 g before and after intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 165
Study: 15076628

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis strain Bb 12 (BbF)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional formula (CF)
Number of subjects: 90
Study: 11755326

Group type: COMPARATOR
Intervention: TENS turned off
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TENS activated
Number of subjects: 40
Study: 9388128

Group type: EXPERIMENTAL
Intervention: 20-mg lovastatin for 6 months
Number of subjects: 0
Study: 8189778

Group type: EXPERIMENTAL
Intervention: Full intervention (FI)
Number of subjects: 2725

Group type: COMPARATOR
Intervention: Limited intervention (LI)
Number of subjects: 2725
Study: 31232840

Group type: EXPERIMENTAL
Intervention: Standard occlusive dressing method (hydrogel or alginate and hydrocolloid compounds)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified dressing method (transparent hydrocolloid films replaced by Vaseline gauze)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (gauze swabs soaked in normal saline)
Number of subjects: 60
Study: 28727955

Group type: EXPERIMENTAL
Intervention: Child-oriented dietary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25936632

Group type: EXPERIMENTAL
Intervention: Clindamycin-rifampicin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clindamycin-levofloxacin (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 23380428

Group type: EXPERIMENTAL
Intervention: Tizanidine PIC® 4 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sirdalud® 4 mg
Number of subjects: 36
Study: 20655664

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 16

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 16
Study: 18435375

Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate‐based cavity disinfectant
Number of subjects: 126

Group type: COMPARATOR
Intervention: No chlorhexidine‐gluconate‐based cavity disinfectant
Number of subjects: 126
Study: 16941685

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg) monotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg) in combination with ribavirin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Follow-up after treatment
Number of subjects: 38
Study: 14613633

Group type: EXPERIMENTAL
Intervention: Topical ivermectin (lotion)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Thiabendazole (ointment and lotion)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Metrifonate (lotion)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 108
Study: 10731624

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 9363714

Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH) therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 81
Study: 1389519

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 600 mg/m2 plus leucovorin (LV) 500 mg/m2
Number of subjects: 148

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) 600 mg/m2 alone
Number of subjects: 148
Study: 3159698

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 30
Study: 30897303

Group type: EXPERIMENTAL
Intervention: Routine Viral Load (RVL) monitoring every six months
Number of subjects: 647

Group type: COMPARATOR
Intervention: Targeted Viral Load (TVL) strategy (routine CD4 plus VL testing if clinical or immunological failure)
Number of subjects: 647
Study: 29377807

Group type: EXPERIMENTAL
Intervention: Multimodal Tongue Drive System (mTDS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Keyboard-and-mouse (KnM)
Number of subjects: 15
Study: 26671307

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (withdrawal of treatment) for 2 weeks
Number of subjects: 30
Study: 24736801

Group type: EXPERIMENTAL
Intervention: Dependence Scale (DS)
Number of subjects: 0
Study: 22304968

Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine (CAM) treatments
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1004
Study: 20554710

Group type: EXPERIMENTAL
Intervention: naive acromegaly patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 16
Study: 17391505

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 16275967

Group type: EXPERIMENTAL
Intervention: Oral therapy with magnesium oxide, Lactobacillus acidophilus, and simethicone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Intravenous hydration, nasogastric-tube decompression and nothing by mouth (control)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 128